CBT
NVAX icon

Central Bank & Trust’s Novavax NVAX Stock Holding History

Central Bank & Trust’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$45K – 291
2020
Q4 		$45K Hold
400
– – 0.01% 211
2020
Q3 		$43K Hold
400
– – 0.01% 201
2020
Q2 		$33K Buy
+400
New +$15.3K 0.01% 196

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Central Bank & Trust's NVAX Position: Q1 2021 in Review

Central Bank & Trust sold out of Novavax (NVAX) in Q1 2021, closing a stake of 400 shares — an estimated $45K sold.

Central Bank & Trust first reported a position in NVAX in Q2 2020 and held it in 3 quarters. The position peaked at $45K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Central Bank & Trust reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Central Bank & Trust sold 400 Novavax shares in Q1 2021, an estimated $45K.
  • Central Bank & Trust first reported a position in Novavax in Q2 2020 and held it in 3 quarters.
  • Central Bank & Trust's Novavax position peaked at $45K in Q4 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Central Bank & Trust's 13F filing for Q1 2021, filed 20 Apr 2021.